|
|
Grace C. Blitzer
University of Wisconsin-Madison, Madison, WI
“I am planning on obtaining my M.D. and becoming an oncologist. I will continue in cancer research, using the AACR meetings as a way to improve my knowledge of new discoveries and inspire my research.”
Abstract 2352: Molecular profiles of head and neck cancer tumorgrafts.
PO.TB01.03 Animal Models of Epithelial, Neuronal and Pulmonary Malignancies
April 2, 1:00 p.m. - 5:00 p.m.
|
|
|
Sara K. Coulup
University of Colorado Boulder, Boulder, CO
“My plan is to pursue a Ph.D. in medicinal chemistry with a focus in synthetic organic chemistry. I hope to use my degree to conduct research towards the development of small molecule drug candidates that target cancer and other diseases.”
Abstract 4745: Multivalent dendrimeric peptides as new biomarker probes for the detection of cancer metastasis.
PO.CH02.01 Chemical and Structural Biology of Cancer
April 3, 1:00 p.m. - 5:00 p.m.
|
|
|
Victoria E. Deneke
Indiana University School of Medicine-South Bend, Notre Dame, IN
“I have an interest in pursuing a Ph.D. program with a focus on biomedical engineering or cancer biology. After my graduate studies, I want to continue researching in the cancer field and eventually start my own multidisciplinary research laboratory at a university, developing molecular mechanisms to better target cancer cells.”
Abstract 2183: Determining the functional roles of the specific isoforms of ARID3B from cellular localizations.
PO.MCB04.04 Nuclear Oncogenes and Tumor Suppressor Genes
April 2, 1:00 p.m. - 5:00 p.m.
|
|
|
Lois M. Dodson
University of Michigan, Ann Arbor, MI
“I seek to continue learning how my work with histone methyltransferases relates to cancer biology as a whole. After graduation I will pursue an M.D./Ph.D. degree. I hope to make contributions to the field as a physician scientist.”
|
|
|
Jerry Fong
Washington University, St. Louis, MO
“I hope to pursue an M.D./Ph.D. in biomedical engineering. With this background, I hope to conduct research as a primary investigator, practice in the clinic and teach at the university level.”
Abstract 1457: Valproic acid enhances radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells.
PO.TB09.01 Radiosensitizers and Radioprotectors
April 2, 8:00 a.m. - 12:00 p.m.
|
|
|
Wenji Guo
University of Illinois at Chicago, Chicago, IL
“My long-range aspiration is to become a scientist and oncologist with the major priority of running an active cancer research laboratory as a primary investigator. […] My goal is to pursue a joint M.D./Ph.D. through the Medical Scientist Training Program funded by the NIH at a world-class research institution.”
Abstract 4322: Iron increases the invasiveness of prostate cancer cells in vitro: Mechanisms and inhibition by the antioxidant ebselen.
PO.TB10.03 Migration and Invasion 3
April 3, 1:00 p.m. - 5:00 p.m.
|
|
|
Selena Kuo
University of California, San Diego, La Jolla, CA
“In the future, I plan to earn an M.D./Ph.D. degree. Being a physician-scientist will allow me to have the closeness to my patients while still fulfilling my interest in research.”
Abstract 3378: Metformin protects head and neck cancer stem cells against DNA damage induced apoptosis.
PO.TB02.06 Identification and Targeting of Cancer Stem Cells
April 3, 8:00 a.m. - 12:00 p.m.
|
|
|
Russell J. Ledet
Southern University and A&M College, Baton Rouge, LA
“I want to focus on educating underrepresented populations on this disease and preventative measures. In order to accomplish this, my goal is to obtain a dual degree M.D./Ph.D. in cancer biology.”
Abstract 5735: Synthesis and characterization of PEG-ylated porphyrins for targeting the epidermal growth factor receptor in colorectal cancer detection.
PO.CH04.01 Chemical Aspects of Carcinogenesis / Imaging Agents and Radiotherapeutics
April 4, 8:00 a.m. - 12:00 p.m.
|
|
|
Daniel O. Macaulay
Prairie View A&M University, Prairie View, TX
“I am particularly interested in the area of prostate cancer research. I expect to graduate and try to get into a graduate program at any of the universities within the U.S. with a good biomedical/cancer research track, and I am considering enrolling for an M.D./Ph.D. program.”
Abstract 4773: Synergistic effects of chitosan and docosahexanoic acid on osteopontin expression and secretion in an ovarian cancer cell line, SKOV-3
PO.CH01.04 Drug Design 2
April 3, 1:00 p.m. - 5:00 p.m.
Abstract 3931: Progesterone and estrogen affect the expression and secretion of heparin binding epidermal growth factor like growth factor (HB-EGF) in RL95-2 cells, an endometrial cancer cell line
PO.EN01.02 Steroid Hormone Receptor and Growth Factor Actions in Cancer 2
April 3, 8:00 a.m. - 12:00 p.m.
|
|
|
Clarissa R. Martins
University of Nevada, Reno, NV
“With my interest in medicine and now my fascination with cancer research I have decided that the best way for me to fight back against cancer is to become a pediatric oncologist, and I would like to continue on in research.”
Abstract 5440: Upregulation of prostaglandin E2 and TGF-alpha by linoleic acid enhances pro-oncogenic signaling in models of human lung and breast cancer.
PO.PR01.06 Preclinical Prevention Studies 6: Dietary and Nutritional Interventions
April 4, 8:00 a.m. - 12:00 p.m.
|
|
|
Gael R. Nicolas
University of South Florida, Tampa, FL
“Attending the national conference provides me with many opportunities to meet with many different professionals and experts in different fields of cancer research. It is my hope that these connections will have a significant influence on where I will continue my education and research.”
Abstract 2897: Preferential drug delivery to cancer cells than to normal cells by using the Niosome-Chitosan Thermo-Responsive Double Package System (NCTR-DPS).
PO.CH06.02 Nanoscale Drug Delivery Systems 2
April 2, 1:00 p.m. - 5:00 p.m.
|
|
|
Elham Rahimy
University of California, San Diego, San Diego, CA
“After graduating, I intend to enroll in an M.D./Ph.D. program to pursue a career as a physician-scientist. I hope to specialize in medical oncology while continuing my passion for cancer research, specifically by investigating and developing novel therapeutic strategies to target cancer stem cells.”
Abstract 422: Nanog promotes PI3K/Akt and mTOR-mediated invasion in head and neck squamous cell carcinoma.
PO.TB02.05 Markers of Cancer Stem and iPS Cells
April 1, 1:00 p.m. - 5:00 p.m.
|
|
|
John L. Robinson
University of South Florida, Tampa, FL
“My plans for the future include becoming a physician-scientist, gaining a strong background in cancer immunotherapy. I plan on putting all my efforts toward translational research.”
|
|
|
Connie R. Shi
University of Michigan, Ann Arbor, MI
“In the future, I am interested in working with a multidisciplinary team in a university setting and using my clinical and research expertise to improve outcomes for cancer patients.”
Abstract 5622: Effect of novel RhoC inhibitor on breast cancer progression and metastasis in vivo.
PO.ET07.04 Exploiting Cancer Biology to Find Novel Drugs, Including Natural Products
April 4, 8:00 a.m. - 12:00 p.m.
|
|
|
Ronald F. Siebenaler
The Ohio State University, Columbus, OH
“I plan to pursue a combined M.D./Ph.D. and specialize in hematology/oncology to conduct translational research that will help improve survival and the standard of care for patients with acute myeloid leukemia or AML.”
|
|
|
Helen Unger
Yeshiva University, New York, NY
“After completing my undergraduate degree in biology, I would like to pursue graduate studies in the biomedical sciences. At this time, my research experience has been mainly in the field of cancer genetics, but I am eager to explore many new areas in biology. After earning my graduate degree, I would like to conduct research in academia, which would allow me to be involved in teaching.”
Abstract 2253: New targets of mTORC1 pathway in ER-positive cells.
PO.MCB01.07 PI3-Kinase/Akt Signaling
April 2, 1:00 p.m. - 5:00 p.m.
|
|
|
Jimmy N. Vo
University of Arkansas, Fayetteville, AR
“I wish to continue my path towards becoming a medical scientist in cancer immunotherapy.”
Abstract 1535: Intratumoral chitosan/interleukin-12 immunotherapy reduces breast cancer metastasis.
PO.IM02.01 Immune Targeting the Tumor Microenvironment
April 2, 8:00 a.m. - 12:00 p.m.
|